Metformina + Sitagliptina Bluepharma

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina, is a biguanide presented as an oral tablet for oral use. It is combined with sitagliptin, a DPP‑4 inhibitor, to treat type 2 diabetes mellitus in adult patients requiring additional glycemic control.

GNH USA supplies Metformina + Sitagliptina as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards and regulatory oversight. Our distribution network ensures timely delivery and supports local regulatory requirements. We also offer technical assistance for product handling.

Metformina + Sitagliptina is used in the management of type 2 diabetes mellitus, an endocrine disorder characterized by elevated blood glucose. - Type 2 diabetes mellitus (adult): improves overall glycemic control when metformin alone is insufficient. - Type 2 diabetes mellitus (fasting glucose): lowers fasting plasma glucose levels. - Type 2 diabetes mellitus (post‑prandial glucose): reduces post‑prandial glucose excursions. - Type 2 diabetes mellitus (HbA1c): decreases glycated hemoglobin (HbA1c) values.

Metformina + Sitagliptina may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Headache: transient cranial pain. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic condition. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hypersensitivity reactions: including skin rash, angioedema, or anaphylaxis.

Before initiating Metformina + Sitagliptina, several precautions should be considered to ensure safe use. - Renal function assessment: evaluate creatinine clearance before and during therapy. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Risk of hypoglycemia: caution when combined with insulin or sulfonylureas. - Elderly patients: start at lower dose and monitor for tolerance. - Cardiovascular status: contraindicated in severe heart failure (NYHA Class IV). - Store at room temperature: keep in original packaging, protect from moisture and heat.

Metformina + Sitagliptina can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant insulin secretagogues (e.g., sulfonylureas): may cause severe hypoglycemia. - Iodinated contrast agents: can precipitate metformin‑associated lactic acidosis in renal impairment. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may enhance metformin’s glucose‑lowering effect. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Warfarin: may require INR monitoring due to potential interaction. - Oral corticosteroids: may reduce antidiabetic efficacy.